Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Express Scripts

Last Updated: September 27, 2022

Sulfur hexafluoride lipid-type a microspheres - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for sulfur hexafluoride lipid-type a microspheres and what is the scope of freedom to operate?

Sulfur hexafluoride lipid-type a microspheres is the generic ingredient in one branded drug marketed by Bracco and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sulfur hexafluoride lipid-type a microspheres has ten patent family members in nine countries.

One supplier is listed for this compound.

Summary for sulfur hexafluoride lipid-type a microspheres
Recent Clinical Trials for sulfur hexafluoride lipid-type a microspheres

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bracco Diagnostics, IncPhase 3
Children's Hospital of PhiladelphiaPhase 3
Children's Mercy Hospital Kansas CityPhase 2

See all sulfur hexafluoride lipid-type a microspheres clinical trials

Pharmacology for sulfur hexafluoride lipid-type a microspheres
Anatomical Therapeutic Chemical (ATC) Classes for sulfur hexafluoride lipid-type a microspheres

US Patents and Regulatory Information for sulfur hexafluoride lipid-type a microspheres

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bracco LUMASON sulfur hexafluoride lipid-type a microspheres FOR SUSPENSION;INTRAVENOUS 203684-001 Oct 15, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Bracco LUMASON sulfur hexafluoride lipid-type a microspheres FOR SUSPENSION;INTRAVENOUS 203684-001 Oct 15, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Bracco LUMASON sulfur hexafluoride lipid-type a microspheres FOR SUSPENSION;INTRAVENOUS 203684-001 Oct 15, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for sulfur hexafluoride lipid-type a microspheres

Country Patent Number Title Estimated Expiration
Brazil 112020022883 formulação liofilizada para microvesículas preenchidas com gás See Plans and Pricing
Japan 2021529730 ガスが充填された微小胞のための凍結乾燥製剤 See Plans and Pricing
Australia 2019298652 Freeze-dried formulation for gas-filled microvesicles See Plans and Pricing
European Patent Office 3817777 FORMULATION LYOPHILISÉE POUR MICROVÉSICULES REMPLIES DE GAZ (FREEZE-DRIED FORMULATION FOR GAS-FILLED MICROVESICLES) See Plans and Pricing
Singapore 11202010539R FREEZE-DRIED FORMULATION FOR GAS-FILLED MICROVESICLES See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for sulfur hexafluoride lipid-type a microspheres

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1556389 16C0004 France See Plans and Pricing PRODUCT NAME: CEFTOLOZANE,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,PLUS PARTICULIEREMENT UN SEL D'ACIDE SULFURIQUE; REGISTRATION NO/DATE: EU/1/15/1032 20150922
1556389 92943 Luxembourg See Plans and Pricing PRODUCT NAME: CEFTOLOZANE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER UN SEL D'ACIDE SULFURIQUE (ZERBAXA); FIRST REGISTRATION: 20150922
1556389 SPC/GB16/002 United Kingdom See Plans and Pricing PRODUCT NAME: CEFTOLOZANE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN PARTICULAR A SULFURIC ACID SALT.; REGISTERED: UK EU/1/15/1032 20150922
1345920 SPC/GB14/018 United Kingdom See Plans and Pricing PRODUCT NAME: MACITENTAN, WHICH IS N-(5-(4-BROMOPHENYL)-6-(2((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)-N'-PROPYLSULFURIC DIAMIDE; REGISTERED: UK EU/1/13/893 20131220
1556389 2015/074 Ireland See Plans and Pricing PRODUCT NAME: CEFTOLOZANE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR A SULFURIC ACID SALT; REGISTRATION NO/DATE: EU/1/15/1032/001 20150918
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
AstraZeneca
McKinsey
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.